Chemi-Verse™ SIK1 Kinase Assay Kit

Catalog #
82105
$745 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The Chemi-Verse™ SIK1 Kinase Assay Kit is designed to measure SIK1 (salt-inducible kinase 1) kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant SIK1 kinase, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.

Synonyms
SNF1LK, MSK, SIK1, salt-inducible protein kinase 1, SNF1-like kinase
Product Info
Storage and Usage
Citations
Assay Kit Format
Luminescent
Materials Required But Not Supplied
  • ADP-Glo™ Kinase Assay (Promega #V6930)
  • DTT (Dithiothreitol), 1M, optional
  • Microplate reader capable of reading luminescence
  • Adjustable micropipettor and sterile tips
  • 30°C incubator
Format
Catalog # Name Amount Storage
  SIK1 1.25 µg -80°C
79334 5x Kinase Buffer 1 1.5 ml -20°C
79686 500 µM ATP 50 µl -20°C
  Amara Peptide (1 mg/ml) 500 µl -20°C
79696 White 96-well plate 1 Room Temp

*The concentration of the protein is lot-specific and will be indicated on the tube.

UniProt #
P57059
Background

SIK (salt-inducible kinases) are serine/threonine kinases of the AMPK (AMP-activated protein kinase) family. They are involved in gluconeogenesis and lipid metabolism inhibition. Dysfunction of SIK has been linked to cancer, due to its association with the TGFβ (transforming growth factor β)-Smad, AKT (protein kinase B), Hippo and NF-κB (nuclear factor kappa-light chain enhancer of activated B cells) pathways. The role of SIK proteins in cancer is complex, with some family members acting as oncogenes while others functioning as suppressors. SIK1 is present at high levels in the adrenal cortex, adipose and neural tissues. SIK1 acts as tumor suppressor in ovarian, lung, colorectal and breast cancer, pancreatic and hepatocellular carcinoma. It inhibits the epithelial-mesenchymal transition (EMT) by downregulating transcription factors involved in inhibition of E-cadherin expression, such as ZEB1 (zinc-finger E-box binding homeobox 1) and ZEB2. MicroRNAs, such as miR-141 and miR17, target SIK1 and promote cancer progression. The development of SIK inhibitors is the focus of intense research, but further studies are needed to identify isoform-specific inhibitors that can be used in cancer therapy.

References

Sun Z., et al., 2020, Signal Transduction and Targeted Therapy 5:150.